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Abstract
Breast cancers that are ‘‘triple-negative’’ for the clinical markers ESR1, PGR, and HER2 typically belong to the Basal-like
molecular subtype. Defective Rb, p53, and Brca1 pathways are each associated with triple-negative and Basal-like subtypes.
Our mouse genetic studies demonstrate that the combined inactivation of Rb and p53 pathways is sufficient to suppress
the physiological cell death of mammary involution. Furthermore, concomitant inactivation of all three pathways in
mammary epithelium has an additive effect on tumor latency and predisposes highly penetrant, metastatic
adenocarcinomas. The tumors are poorly differentiated and have histologic features that are common among human
Brca1-mutated tumors, including heterogeneous morphology, metaplasia, and necrosis. Gene expression analyses
demonstrate that the tumors share attributes of both Basal-like and Claudin-low signatures, two molecular subtypes
encompassed by the broader, triple-negative class defined by clinical markers.
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Introduction
The dire need for more effective treatments for aggressive breast
cancers has motivated intensive investigations into their cellular
and molecular etiology. Breast cancers classified as ‘‘triple-
negative’’ by clinical diagnostic markers (ESR1, PGR, and
HER2 negative) are heterogeneous in their clinical behavior,
morphology, and molecular biology. Triple-negative breast
cancers (TNBC) typically express the Basal-like molecular
signature, thus TNBC and Basal cancer classifications are
frequently used interchangeably. However, they are not com-
pletely synonymous [1,2]. TNBCs also include the Claudin-low
molecular subtype [3], which is characterized by greatly reduced
expression of intercellular junction components and by activation
of molecular pathways associated with epithelial-to-mesenchymal
transition (EMT), cancer stem cells, and the immune response [4].
Histologically, most triple-negative breast cancers are invasive ductal
carcinomas, but TNBCs also include the metaplastic, medullary, and
adenocystic histologic special types, distinctive morphologies that are
prevalent among Claudin-low tumors [4]. TNBCs are insensitive to
endocrine therapy and HER2 antagonists, but they are sensitive to
chemotherapy. Nevertheless, long-term patient outcomes are poor due
to high rates of relapse and acquired chemoresistance [5,6]. Mouse
models that mimic the complexity of TNBCwill be invaluable tools for
defining the diverse cellular biology and behavior of these tumors and
for rigorously triaging new drug candidates.
Basal-like breast cancers often simultaneously inactivate three
tumor suppressors that are infamous for their roles in familial
cancers: Rb (RB1) [7], p53 (TP53) [8], and BRCA1 [9]. p53 is
mutated in 20–30% of human breast cancers and defective
pathway intermediates also increase breast cancer risk [10].
Moreover, nearly all Basal-like cancers with BRCA1 mutation have
concomitant p53 mutation [11]. Germline BRCA1 mutation
predisposes early-onset breast cancers that are often triple-negative
and that correlate with Basal-like tumors in microarray analyses
[9]. BRCA1 mutation accounts for nearly half of familial breast
cancers (OMIM 604370), but BRCA1 is also down-regulated in
sporadic breast tumors without germline mutation [12]. The
overall effect of BRCA1 loss is likely pleiotropic. The best studied
function of BRCA1 is in orchestrating DNA double-strand break
repair through homologous recombination or non-homologous
end-joining. The importance of defective DNA repair in breast
cancer is underscored by the observation that all known genes
associated with inherited forms of the disease safeguard genomic
integrity [13]. BRCA1 also functions as a transcription factor [14]
that appears to be required for the differentiation of stem/
progenitor cells into mature luminal cells [15]. This finding is
consistent with the recent characterization of BRCA1-associated
tumors as aberrant luminal progenitor cells [16].
The pair-wise cooperativity of Brca1 and p53 in mammary
tumorigenesis has been studied in mouse models [17]. We and
others have investigated the impact of combined Rb and p53
inactivation on mammary tumorigenesis in vivo [18–20]. We
showed that following Rb perturbation in vivo, tumor progression is
limited largely by p53-dependent apoptosis, and that loss of the
second p53 allele in MFT121+/p53f/+ tumors is likely a prerequisite
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for mammary tumor progression [19], since the vast majority of
tumors lose the wild type p53 allele during tumorigenesis. In the
context of a brain carcinoma model initiated by T121, apoptosis
appears to be the critical function of the normal p53 allele that is
the target of selective pressure [21].
Our motivation to combine Rb inactivation with Brca1 and p53
mutation derives, in part, from the observation that the Rb gene is
among the most frequently deleted loci in Brca1/p53-mutated
mouse tumors [22], indicating that Rb is a critical barrier to tumor
progression. Rb pathway inactivation is strongly associated with
human triple negative breast cancers. A cardinal feature of basal-
like breast cancers is the abundant expression of the ‘‘proliferation
cluster’’ genes [7], which include many E2F-regulated genes that
are de-repressed following Rb inactivation. In human breast
cancers, reduced pRb activity correlates with higher tumor grade
[23], but also predicts improved chemotherapy responsiveness [24].
The Rb gene itself is mutated in breast cancer [25], and recent
genomic studies have indicated an overrepresentation of mutations
within pRb-binding sites of human gene regulatory domains [26].
In this study we show that mammary tumors caused by
inactivation of the pRb family (pRbf) of proteins (pRb, p107, p130),
together with Brca1 and p53 inactivation, mimic several aspects of
the most aggressive forms of breast cancer, including rapid tumor
progression, poor differentiation, distant metastasis, necrosis,
metaplasia, and genomic instability. Our findings illustrate the
compounding effect of acquiring multiple tumor suppressor
mutations during tumor evolution and underscore the distinct
requirements of each of these canonical tumor suppressor proteins.
Results
Conditional T121 expression in mammary epithelium
We constructed the MFT121 (MMTV-Floxed-eGFP-T121) trans-
gene to conditionally inactivate the pRb family (pRbf) of pocket
proteins in mammary epithelium (Figure 1A). The T121 protein is an
amino-terminal fragment of the SV40 large T antigen that perturbs
pRbf activity and predisposes tumorigenesis in a range of tissues
[27]. While Rb inactivation alone is sufficient to induce mammary
tumors [20], the shorter latency of TgWAP-T121 tumors indicates
there is functional redundancy or compensation by the related
pocket proteins p107 or p130 [19]. In the MFT121 model, the
MMTV-LTR promotes mammary-specific transgene expression
(Figure 1B). The approach of inactivating pRBf, Brca1, and p53
specifically in mammary epithelial cells via the Wap-Cre transgene
[28] enabled us to avoid the appearance of lymphomas [20] or
sarcomas [29]. Wap-Cre excised the LoxP-eGFP-stop-LoxP
reporter cassette and initiated T121 expression in ductal and
alveolar luminal epithelial cells (Figure 1C). Virgin glands of
MFT121; WAP-Cre mice appeared normal. Lactating glands (WAP-
Cre-induced) showed reduced alveolar density, similar to the gland
atrophy phenotype in the TgWap-T121 model, which was associated
with apoptosis caused by T121-induced proliferation [19] and
lactation defects observed in WAP-Cre; Rbfl/fl; p1072/2 mice [20].
Concomitant pRbf, p53, and Brca1 inactivation
significantly accelerates tumor onset
Multiparous TgMFT121; TgWap-Cre mice remained tumor-free
for more than a year after Cre-induction, but mice that were either
Figure 1. The MFT121 transgene construct. (A) The MFT121
transgene construct. The ‘‘floxed’’ eGFP-stop cassette was expressed
throughout virgin mammary epithelium (B, original magnification 506).
Following Cre-induced excision, T121 was expressed (red) in the majority
of luminal epithelial cells (C). eGFP immunolabeling (green) revealed
non-recombined cells (original mag. 4006). Kaplan-Meier analysis of
tumor onset (D). p53 was haploinsufficient (dashed green) for tumor
suppression (p,0.0001, log-rank test). Homozygous p53 mutation (solid
green) shortened tumor latency. Brca1 loss (solid red) further
accelerated tumor onset (p,0.0005). Median tumor latency of TBP
mice was approximately seven weeks. Parturition Day 1 = Time 0. All
mice harbored the Wap-Cre transgene (not shown). Significance levels
for critical comparisons are indicated.
doi:10.1371/journal.pgen.1003027.g001
Author Summary
These studies establish a unique animal model of
aggressive forms of breast cancer for which there are no
effective, targeted treatments. Rb, p53, and Brca1 are
associated with inherited forms of cancer, but defects in
these pathways are also found together in a subset of
breast cancer patients without a family history of the
disease. Simultaneous inactivation of all three pathways
causes more aggressive disease than do pair-wise combi-
nations, indicating that the pathways play non-overlap-
ping roles in tumor prevention.
Genetic Interaction of pRb, Brca1, and p53
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heterozygous or homozygous for a conditional p53 allele [30]
(TgMFT121; TgWAP-Cre; p53
f/+ or TgMFT121; TgWAP-Cre; p53
f/f)
developed mammary tumors with 100% penetrance and clear
evidence of p53 haploinsufficiency (Figure 1D, p,0.0001, log-rank
test). Heterozygous p53 mice developed tumors with a median
latency of 299 days, while p53 homozygous mice had a median
tumor latency of 150 days. These results are consistent with
previous findings that p53 activity is rate limiting for mammary
tumor progression initiated by Rb inactivation [18–20]. In contrast
to the high penetrance we previously found in our TgWAP-T121
breast tumor model [19], the present studies indicate that the
TgMFT121 transgene only partially inhibits pRbf pathways,
possibly owing to the reduction in the transgene gene copy
number following Cre excision. Similar dosage effects were
observed in a conditional T121 transgenic model of astrocytoma
[31].
Brca1 mutation dramatically accelerated tumor onset in mice
with Rbf/p53 inactivation (Figure 1D, p,0.0005). Only a single
mouse (n = 13), doubly defective for Rbf and Brca1 activity
(TgMFT121;TgWAP-Cre;Brca1
f/f), developed mammary tumors at
386 days following Cre induction by multiple pregnancies. In
contrast, 100% (n= 10) of TgMFT121; Brca1
f/f p53f/f; TgWAP-Cre
mice (hereafter, TBP) developed mammary tumors with a median
latency of only 47 days. Thus, a single pregnancy was sufficient for
100% TBP tumor penetrance. Once palpable, TBP tumors grew
rapidly to 1500 cc within several days (data not shown). Therefore,
inactivation of the three canonical tumor suppressors showed
additive effects on tumor latency, since TBP mammary tumors
developed significantly faster than did pair-wise combinations.
Enhanced survival and increased proliferation rates cause
rapid tumor progression in pRbf/p53/Brca1-perturbed
epithelium
To investigate the early effects of tumor suppressor inactivation,
we examined mammary gland biopsies (n = 5 mice) from time
points (0, 2, 6 weeks) following forced weaning at Day 1
parturition. At the earliest time point, T121 expression alone was
sufficient to cause benign, hyperproliferative lesions (Figure 2A,
2B). T121-expressing cells showed a higher Ki67 index than did
cells without T121, as expected (p,0.0063, Figure 3P). Combina-
tions with Brca1 and p53 mutation caused higher grade,
premalignant lesions (Figure 2C–2F). Tall columnar epithelia of
darkly staining cells and papillary tufting (Figure 2C) were
characteristic of the disrupted epithelial morphology. Pleomor-
phic, faintly staining nuclei with prominent nucleoli were common
among T121 expressing cells (Figure 3F).
The combined inactivation of pRbf and p53 also dramatically
suppressed the physiologic cell death of mammary involution
(Figure 3I, 3N), although pRbf perturbation alone had little effect
(Figure 3B, 3G, 3L). It was shown that p53 mutation alone delayed
involution by several days [32]. Here, we observed that the
combined inactivation of pRbf and p53 blocked involution
through six weeks (Figure 3I, 3N). Biopsies from mice harboring
Brca1 mutation (Figure 3C, 3J) showed extensive cellular debris
from dead or dying cells within their lumen. The dual loss of pRbf
and Brca1 activities (TgMFT121;TgWAP-Cre;Brca1
f/f) triggered
elevated cell death that was p53-dependent (p,0.0001,
Figure 3Q). The combined loss of pRbf, Brca1, and p53 activities
accelerated tumor progression, indicated by frank tumors that
appeared by six weeks (Figure 3O). However, when measured at
the earliest time point, neither an increased Ki67 proliferation
index (Figure 3P) nor a decreased cell death index (Figure 3Q)
presaged faster onset of TBP tumors compared to Rbf/p53 tumors.
Thus, full transformation occurred in only a minority cell
population, which likely reflects the requirement for additional
collaborating oncogenic events.
Histopathologic features of tumors with conditional
inactivation of pRbf, p53, and Brca1
T121/p53 (TP) and TBP mice developed high grade mammary
adenocarcinomas with heterogeneous phenotypes indicative of
highly perturbed differentiation, summarized in Table 1. Tumors
of both genotypes showed mixed solid and glandular morpholo-
gies. More TBP mice than TP mice (13/14 vs. 8/16 cases,
p = 0.0169, two-tailed Fisher’s exact) developed solid tumors that
were largely devoid of glandular architecture (Figure 4A). All solid
tumors showed a mixture of pushing and infiltrative borders, and
nearly half of the tumors were vascularized (Figure 4A). All
carcinomas expressed varying levels of luminal epithelial markers,
including Keratin-8 (Figure 4E, 4G, 4K) and E-Cadherin
(Figure 4I, 4L). These markers were abundant in well-differenti-
ated tumor regions but were greatly diminished or absent in poorly
differentiated areas (Figure 4E, 4I, 4K, 4L). Nests of carcinoma
cells variably expressed basal/myoepithelial lineage markers
(Keratins-5, -14, Figure 4E, 4K).
Both TP and TBP mice (4/16 vs. 1/14 cases, p = 0.3359)
developed carcinosarcomas (Figure 4C), also known as ‘‘EMT’’
(Epithelial to Mesenchymal Transition) tumors [33]. These tumors
are comprised of faintly-staining, fusiform, spindloid cells and are
characteristic of p53 mutant mice. The histology of hematoxylin
and eosin stained carcinosarcomas is relatively homogeneous and
is visibly distinct from carcinomas with spindloid metaplasia that
showed biphasic carcinomatous and spindloid morphologies
(Figure 4B, 4G). Among both carcinosarcomas and metaplastic
tumors, we observed dual expression of mesenchymal (Vimentin)
and epithelial (Keratin-8) markers (Figure 4G), which are mutually
exclusive lineage markers in the normal gland. Dual expression is
also a feature of human Claudin-low [4] and mouse EMT tumors
[33]. Poorly differentiated spindloid cells along invasive tumor
fronts showed either dual expression (Figure 4G) or greatly
diminished epithelial marker expression (Figure 4J–4L).
In both TP and TBP tumors, we observed squamous metaplasia
that was characterized by keratin nests (Figure 4M) and high
expression of Keratin 6 (Figure 4N), a marker of progenitor cells
that is expanded in Wnt-1-induced mammary tumors. Four of
fourteen cases (29%) of TBP tumors, but zero cases of TP tumors
(p = 0.0365), included whorls of spindloid cells that resembled
myoepithelial cells (not shown). Finally, central necrosis, a
hallmark feature of human BRCA1-mutated tumors, was present
in twelve of fourteen TBP cases, a greater proportion than the
eight of sixteen T121/p53 cases (p = 0.0577), indicating that the
selective pressure of cell death persists even in the absence of p53
activity.
Distant metastases were observed in the lungs of both TP (4 of
14 cases) and TBP (3 of 6 cases) mice (Figure 4P), which is
noteworthy because relatively few transgenic mammary tumor
models metastasize. Among mouse models that do metastasize,
most are derivatives of the PyMT model, which more closely
resembles human Luminal subtype tumors than Basal-like tumors
[3]. Metastases were not evident in the sternum, liver, or spleen of
these mice. A primary cell line established from a TBP tumor
formed secondary tumors following serial transplantation into
syngeneic (FVB) mammary fat pads (Patel, unpublished), confirm-
ing the malignant capacity of TBP tumors.
In summary, TBP tumors displayed heterogeneous histology,
including high grade, central necrosis, metaplasia, pushing
boarders, and metastasis, features that are characteristic of human
BRCA1-mutated and Claudin-low breast tumors.
Genetic Interaction of pRb, Brca1, and p53
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Global gene expression analysis
The majority of the TgMFT121 mouse tumors (76%) co-
segregated with human Basal-like breast cancers by hierarchical
clustering of the top ,1000 most variable genes in a combined
data set of mouse (n = 135) and human (n= 337) tumor expression
profiles (Figure 5, Figure S1, File S2). Using a similar approach
that we reported previously [3], we assayed global transcript levels
by microarray using tumors derived from TBP (n= 8) and TP
mice (n = 9), and we compared them directly to tumors and
normal tissue from other mouse models [3] and patient samples
[4]. Two TP tumors clustered with human tumors that showed a
mixture of the PAM50 molecular subtypes that were assigned by
Prat and colleagues (2010). The two remaining TP tumors
clustered with Claudin-low subtype human tumors.
The effect of Brca1 mutation on TP tumors was more evident
when we focused our analysis on the mouse specimens alone
(Figure 6, File S3). 56% of the TP tumors (5 of 9) clustered with
mouse tumors that we previously showed resemble human
Luminal tumors [3]. Brca1 mutation shifted the tumor phenotype
(p = 0.0529, Fisher’s exact). All eight TBP tumors segregated with
mouse tumors, including other Brca1-mutant models that more
closely resemble human Basal-like TNBC (Figure 6A). TBP
tumors and the other Basal-like mouse tumors expressed low levels
of luminal markers and high levels of both Proliferation and Basal
cluster transcripts, including Keratins-14, -6b, -17 (Figure 6C). In
contrast, the TP tumors that clustered with Luminal-B-like tumors
(Figure 5A, blue box) showed higher expression of luminal marker
genes that correlate with the estrogen pathway target Xbp1
(Figure 5A). Interestingly, TBP tumors were distinct from most
other Basal-like mouse tumors in their elevated expression of a
subset of Claudin-low signature genes [3,4], including Snail1, Tgfbi,
Dtr, and Timp1 (Figure 6C).
Four TP tumors (44%) did not segregate with Luminal-like
tumors. This finding is consistent with previous reports by us and
Figure 2. Early lesions in lactating mammary glands. (A) Nuclear and cytoplasmic T121 expression (brown) is associated with enlarged,
pleiomorphic nuclei (filled arrows) compared to low-expressing cells (open arrow). (B) Benign, multi-layered, mammary intra-epithelial neoplasia
(MIN) within the same gland as A. (C) Dual inactivation of Brca1 and p53 disrupted epithelial architecture in primary ducts (C) and lactating alveoli (D),
shown by papillary tufting (C, arrows) and high grade nuclei and prominent nucleoli (D, arrows). High grade nuclei and mitotic figures (E, open
arrows) and dead cell debris (arrow) in MFT121; Brca1 gland. Severely pleomorphic and high grade nuclei are visible throughout MFT121; Brca1; p53
gland (F).
doi:10.1371/journal.pgen.1003027.g002
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Figure 3. Combined inactivation of pRbf and p53 causes a durable block in involution. Lactating mammary epithelium of Cre-negative
control mice (A, F, K) and T121-expressing mice (B, G, L) involute normally (A–E: 0 wks, F–J: 2 wks, K–O: 6 wks). T121-expressing mice have reduced
alveolar density. Cell death and debris were abundant in TB glands (arrows panels C, J). TP glands failed to involute (N) and persisted as highly cystic
glands. Frank tumors were present by 6 wks in TBP mice. An invasive adenocarcinoma fills the field of panel O. Measured at 0 wks, T121 increased the
Ki67 index but without added effect by Brca1 and/or p53 loss (P). Combined inactivation of pRbf and Brca1 increased TUNEL-positive cells, which was
suppressed by p53 loss (Q, p,0.0001). For each genotype n= 5 mice. Original magnification of each panel was 2006. T = T121, B = Brca1, P = p53.
doi:10.1371/journal.pgen.1003027.g003
Table 1. Characteristics of TP and TBP tumors.
Histologic Feature TgMFT121,Brca1
f/f,p53f/f TgMFT121, p53
f/+ TgMFT121, p53
f/f
n=14 (%) n=11 n=16
Solid* 13 (93) 6 (55) 8 (50)
Glandular 4 (29) 2 (18) 6 (38)
Spindloid metaplasia 9 (64) 4 (36) 5 (31)
Carcinosarcoma 1 (7) 3 (27) 4 (25)
Squamous Metaplasia 2 (14) 2 (18) 4 (25)
Myoepithelioma* 4 (29) 0 (0) 0 (0)
Cribriform 0 (0) 1 (9) 0 (0)
Invasion 9 (64) 4 (36) 8 (50)
Apoptosis/Necrosis{ 12 (86) 7 (64) 8 (50)
Fibrosis 1 (7) 1 (9) 5 (31)
Angiogenesis 5 (36) 5 (45) 7 (44)
Significant at p,0.05.
*two-tailed.
{one-tailed Fisher’s exact.
Many tumors showed multiple, mixed morphologies; therefore, the percentage reflects the proportion of tumors showing the phenotype within each genotype. We
saw no differences due to the initial p53 allele status (f/+ vs. f/f). We combined these classes (n = 11+16 = 27) for statistical comparison to tumors with Brca1 mutation
(n = 14).
doi:10.1371/journal.pgen.1003027.t001
Genetic Interaction of pRb, Brca1, and p53
PLOS Genetics | www.plosgenetics.org 5 November 2012 | Volume 8 | Issue 11 | e1003027
Figure 4. Perturbed differentiation in TBP tumors. Poorly differentiated tumors with solid morphology were most common (A), with and
without vascularization (white arrows) or central necrosis (asterisk). Other tumors retained remnant glandular architecture (B, white arrows).
Metaplastic cells invaded adjacent muscle and stroma (B, black arrow). Homogeneous spindloid cells of a carcinosarcoma entrap carcinomatous cells
(C, 1006). Keratin-8 (Krt8, green) and Keratin-5 (Krt5, red) immunolabeling of luminal and myoepithelial cells, respectively (D, E, K). Greatly reduced
expression of both Krt5 and Krt8 (E dashed lines, and K arrow). DAPI staining (blue) indicates the high cellularity of the region devoid of epithelial
markers in panel E (F). Metaplastic tumor cells (G) with dual staining of Krt8 (red) and the mesenchymal marker Vimentin (green), or reduced Krt
Genetic Interaction of pRb, Brca1, and p53
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others that Rb/p53 tumors can also resemble TNBC and the
Claudin-low molecular phenotype [3,18,20]. A single TP tumor
clustered among the previously designated Group II tumors
(Figure 6A, yellow box), which are the paradigm cases of the
Claudin-low subtype [3]. In addition, a single TP tumor clustered
with tumors with a squamous metaplastic histology. Finally, two
TP tumors co-segregated with the TBP tumors (Figure 6A, orange
box), which is not surprising given that Rb is one of the most
frequently deleted loci among Brca1/p53-mutated mouse tumors
[22].
Pathway analysis
The similarity between TBP tumors and human Claudin-low
and Basal-like cancers was also evident from pathway analysis of
up-regulated genes of each of the three tumor types (Figure 7A,
File S1). We queried the KEGG (Kyoto Encyclopedia of Genes
and Genomes) and GO (Gene Ontology) databases with lists of
genes that were differentially expressed by TBP tumors (see
Methods) and by human Claudin-low and Basal-like tumors [4].
Cytokine, chemokine, and MAPK signaling pathways ranked
highly among both Claudin-low and TBP tumors. Pathways that
are enriched in cancers of diverse origins ranked highly in both
Basal-like and murine TBP tumors.
The GO terms associated with the respective tumor types were
consistent with the enriched KEGG pathways. Cell-cycle progression
(GO:0007049, p=2.43551E-59) and DNA repair (GO:0034984,
p=6.95081E-22) dominate the list of functions enriched in Basal-like
tumors (File S1). Similarly, regulation of cell proliferation
(GO:0042127, p=6.01E-13) is among the top terms for TBP
tumors. The three top scoring, inter-related GO terms for TBP
tumors are regulation of developmental process (GO:0050793,
p=7.50E-16), organ morphogenesis (GO:0009887, p=3.53E-14),
and tissue development (GO:0009888, p=1.36E-13). These GO
terms are reflective of the enrichment of the Wnt, ErbB, TGF-b, and
VEGF signaling pathways identified by KEGG pathway analysis.
Claudin-low tumors are enriched for wound (GO:0009611,
p=4.29939E-66) and inflammatory responses (GO:0006954,
p=1.26817E-50), which are also among the top functions associated
with TBP tumors (7.37E-13 and 6.46E-12, respectively).
CGH analysis
Given the requirement for BRCA1 in DNA damage repair and
centrosome regulation, we tested the hypothesis that TBP tumors
harbor more genomic copy number aberrations (CNAs) than do
TP tumors with intact Brca1. We enumerated CNAs by counting
‘‘copy number transitions,’’ the number of changes in the CGH
profile from one copy number level to another that occur within
chromosomes [34]. Unexpectedly, we found no statistically
significant difference (p= 0.8374) in the mean number of CNAs
between TBP tumors (n = 8) and TP tumors (n = 10) using array-
based comparative genomic hybridization (aCGH).
The low multiplicity of TBP and TP tumors (1–3 per mouse)
and their latency indicate that combinations of pRbf, Brca1, and
p53 pathway perturbations are not sufficient for malignant
transformation in our models. To identify potentially collaborating
oncogenic events, we manually curated loci with copy number
changes (see Methods). In nine tumors (50%), we observed
recurrent losses of large, variable regions spanning chr4 and chr10
(Figure 8). Both chromosomes harbor many potential tumor
suppressors, including regulators of cell death, such as Tm2d1,
Utp11l, Trp73, Dffa, Runx3, Lck, Dhcr24, Faf1, Pax7, and Casp9, and
effectors of cell death, such as Col18a1, Gadd45b, Dapk3, and
Casp14. Among all the tumors assayed (n= 18), we identified
nearly five-hundred loci (Table S9 in File S1) with potential copy
number gains. Approximately half of the genes are included on
curated lists of cancer-associated genes, including the Cancer
Gene Census (Sanger Institute) and the KEGG Pathways in
Cancer. We observed focal amplification of several canonical
proto-oncogenes, including c-Myc amplification (log2ratio = 3.64,
p,0.0001) in a single TP tumor, H-ras amplification in two of ten
TP tumors, and K-ras amplification in two of eight TBP tumors.
Pathway analysis of these five-hundred putative collaborating
genes revealed enrichment of several signaling pathways, including
the MAP Kinase, Focal Adhesion, Wnt, and ErbB pathways
(Table S10 in File S1).
Discussion
Here we report a highly penetrant engineered mouse model of
TNBC. Our previous work showed that when pRbf and p53 are
simultaneously perturbed in mammary epithelium, adenocarcino-
mas develop with long latency, suggesting a requirement for
additional oncogenic events. However, these mouse tumors
displayed only limited chromosomal copy number aberrations
[19]. Because genomic instability is a hallmark of malignant
transformation [35], especially among BRCA1 familial cancers
[36] and aggressive sporadic breast cancers [37], we hypothesized
that Brca1 mutation would accelerate the tumor development we
observed following dual inactivation of pRbf and p53. Our results
show that concomitant inactivation of all three tumor suppressor
pathways in mammary epithelium has an additive effect on tumor
latency and predisposes highly penetrant, malignant carcinomas.
Although Brca1 inactivation accelerated tumorigenesis compared
to TP tumors, we observed no statistical difference between
chromosomal copy number transitions in tumors with or without
Brca1, despite the extensive CNAs observed by others in Brca1/
p53 tumors [22].
The pRb-regulated cell cycle network is frequently disrupted in
TNBC tumors [7,26,37,38], and the Rb locus is among the most
frequently lost in Brca1/p53 mouse tumors [22], indicating that
there is strong selective pressure for Rb pathway inactivation. We
speculate that direct inactivation of pRbf by T121 may allow TBP
cells to escape this rate-limiting barrier of transformation without
accruing numerous chromosomal aberrations. Thus, in the
context of defective pRb and p53 function, tumor progression
may be unrelated to the proportion of the genome altered by copy
number alterations. It will be important to determine the effect of
Brca1 loss on the abundance and identities of somatic mutations
that are not detectable by CGH.
The importance of p53 mutation in breast cancers is well
documented and is confirmed in the present study. The dual
inactivation of pRbf and Brca1 caused markedly increased cell
death that was reduced by p53 mutation. p53-independent cell death
likely remains a significant barrier to tumor progression among
TBP tumors and may account, in part, for the observed loss of
genomic regions that harbor cell death regulatory genes, most
notably on chr4 where the p53 paralog p73 resides. Identifying the
genomic alterations that are conserved across species will be useful
staining (K). Abundant E-cadherin (CDH1, green) in normal adjacent (H) or well-differentiated tumor (I). Reduced or absent CDH1 along invasive
tumor fronts (J–L). Keratinic whorls in squamous metaplastic cells (M, asterisks). Whorl-associated and disseminated Keratin 6 expression (N, green).
Pulmonary metastases were observed in both T121/p53 and TBP mice (O, arrow).
doi:10.1371/journal.pgen.1003027.g004
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in evaluating the impact of the myriad of CNAs observed in breast
cancers and may help to explain the heterogeneity of TNBCs.
Brca1 mutation not only accelerated tumor development but
also shifted the tumor spectrum. Whereas T121/p53 mouse tumors
often resembled the Luminal-B molecular subtype breast cancers,
which show relatively abundant expression of luminal epithelial
cell differentiation markers, TBP tumors consistently shared
features of Basal-like and Claudin-low molecular subtypes. Others
have argued that Basal-like and Claudin-low gene expression
signatures reflect progenitor and stem cell phenotypes, respectively
[4,16], consistent with a role for Brca1 in mediating stem/
progenitor cell maturation [15]. Loss of BRCA1 activity may also
alter tumor phenotype through deregulation of the EMT inducer
SLUG [39].
The CGH analysis of our mouse tumors revealed CNAs
consistent with mutations observed in genomic surveys of human
breast cancers [40,41]. Similar to the studies of human tumors, we
saw increased copy numbers of known oncogenic driver genes,
including myc, egfr, crebbp, jak1, H-ras, and K-ras, as well as
enrichment of pathways implicated in tumor progression, includ-
ing the WNT signaling pathway, regulation of actin cytoskeleton,
focal adhesion, cell shape, and mobility proteins. Far fewer
investigations have focused on genetic deletions and cancer
development mechanisms. We also found decreased copy numbers
of known tumor suppressors, including map2k, ppp2r, and pten.
Given the strong similarities between our mouse model and
aggressive human breast cancers, the TBP model provides an
invaluable preclinical platform to identify and assess potential
therapeutics for aggressive and chemoresistant breast cancer
subtypes [42,43].
Materials and Methods
Ethics statement
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
Derivation of MFT121 transgenic mice
The LoxP-eGFP-Stop-LoxP cassette and T121-encoding DNA
were cloned into EcoRIHindIII sites ofMMTV-SV40-Bssk (Addgene
plasmid 1824). The LoxP-eGFP-Stop-LoxP cassette was provided
courtesy of the T. Jacks lab. Resulting and subsequent generation
MFT121 transgenic mice were identified by PCR amplification of a
215-bp fragment using the oligo pair: 59-GCATCCAGAAGCCTC-
CAAAG -39 and 59-GAATCTTTGCAGCTAATGGACC-39 com-
plementary to the T121 sequence. Cre transgenic mice were identified
using the oligo pair: 59-TGATGAGGTTCGCAAGAACC-39 and
59-CCATGAGTGAACGAACCTGG-39. The cycling profile was
94uC for 2 min., 35 cycles of 94uC for 20 sec., 62uC for 45 sec., and
72uC for 45 sec.; the final incubation of 72uC was for 2 min. We
established five TgMFT121 founder transgenic lines, though three lines
failed to express the eGFP reporter. We describe here our studies of
the single mouse line with higher eGFP expression in virgin mammary
glands. eGFP expression was also evident in salivary glands and foot
pads in this line (data not shown).
Figure 5. Cross-species comparison of breast cancers. TBP (black
boxes, n = 8) and TP (open black boxes, n = 9) tumors were compared to
published mouse (gray boxes, n = 135) and human (n = 337) microarray
expression profiles (colored according to PAM50 subtype). Most (76%)
of our TgMFT121 mouse tumors cluster with human Basal-like breast
cancers (red boxes). The Treeview files of the clustering analysis are
available in File S2.
doi:10.1371/journal.pgen.1003027.g005
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Transgenic breeding strategies
TgMFT121;TgWAP-Cre mice were mated to p53 conditional allele
mice (p53f/f) [44]. p53 genotypes were determined by PCR using two
reactions: neomycin primer 59-TCCTCGTGCTTTACGGTATC-
39, p53 primer 59-TATACTCAGAGCCGGCCT-39, 525-bp prod-
uct; the endogenous p53 allele; substituting 59-ACAGCGTGGTGG-
TACCTTAT-39 for the neo primer, 475-bp product. Cycling
parameters were the same as they were for the T121 reaction. We
produced female mice with the genotypesTgMFT121;TgWAP-Cre;p53
f/
+ and TgMFT121;TgWAP-Cre;p53
f/f, and female littermates served as
controls. To study the effect of Brca1 loss, TgMFT121; TgWAP-Cremice
were mated to Brca1f/f,p53f/f mice [44]. Brca1 genotypes were
determined by PCR using two reactions. We generated female mice
with the genotypes TgMFT121; TgWAP-Cre; Brca1
f/+,p53f/+ and
TgMFT121; TgWAP-Cre; Brca1
f/f,p53f/f with nontransgenic (Cre
negative) littermate controls for each cohort. Pregnancy induced
WAP-Cre transgene expression. Parturition of the first litter was
designated as Day 1 for all aging studies. Matings with TgMMTV-Cre
mice (Line F) yielded small litter sizes; therefore, experiments reported
here employed TgWap-Cre unless otherwise indicated.
Histopathology and apoptosis assays
A portion of each mammary sample was fixed overnight in 10%
phosphate-buffered formalin, transferred to 70% ethanol, and then
embedded in paraffin. Samples were sectioned for 10 successive layers
at 5-mm intervals and stained with hematoxylin and eosin for
histopathologic examination, as described previously. Apoptosis levels
were assessed using the terminal deoxynucleotidyl transferase–
mediated dUTP-biotin nick end labeling (TUNEL) method with
standard protocols. Differences in apoptosis levels between mice with
different genotypes were evaluated by the t test (p,0.05 was deemed
statistically significant).
Immunostaining
Immunohistochemical analysis was performed using formalin-fixed
paraffin sections. Antigen retrieval for all antibodies was done by
boiling the slides in citrate buffer (pH 6.0) for 15 min. Antibodies were
a-cytokeratins 8/18 (Ker8/18, 1:450 Progen, GP11), a-cytokeratin 5
(K5, 1:8000, Covance, PRB-160P), smooth muscle actin (SMA;
1:1,000, mouse A2537; Sigma, St. Louis, MO), anti–phosphorylated
histone H3 (1:100, rabbit 06-570; Upstate, Waltham, MA) and SV40
Figure 6. TBP tumors share features of Basal-like and Claudin-low expression signatures. (A) Expression of 866 reference genes of TP
(n = 9) and TBP (n = 8) tumors and 13 models of breast cancer. Tumor annotations of the expanded dendrogram (A) are color coded by tumor model.
Selected gene clusters (C) correspond to the full data matrix (B). TBP tumors (orange box) cluster with mouse tumors that more closely resemble
TNBC on the left branch. 56% (5 of 9) of TP tumors clustered with Luminal-B tumors (blue box). TBP tumors show high expression of Snai1-correlated
genes in the Claudin-low cluster. The Treeview files of the clustering analysis are included in Table S1 in File S1.
doi:10.1371/journal.pgen.1003027.g006
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(monoclonal Ab2, 1:100; Oncogene, Cambridge, MA). All immuno-
fluorescence reactions were done using AlexaFlour-conjugated
secondary antibodies (AlexaFluor 488 and 594, Molecular Probes).
Slides were counterstained with 49,6-diamidino-2-phenylindole (DAPI)
using Hardset Mounting Media (Vector Laboratories).
Microarray analysis
We compared microarray profiles of T121/p53 (n= 9) and TBP
(n= 8) tumors to published microarray profiles (n= 152) using two-
way hierarchical clustering (centroid linkage) of 866 ‘‘intrinsic
genes’’ [3,45]. Total RNA was collected from end-stage tumors.
Figure 7. Intersecting KEGG pathway terms. (A) The genes differentially expressed among mouse TBP tumors show enrichment of KEGG
pathways associated with human Claudin-low and Basal-like tumors. (B) The pathway terms are colored according to the intersections depicted in the
Venn diagram. The full KEGG pathway lists are included in Table S1 in File S1.
doi:10.1371/journal.pgen.1003027.g007
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RNA was purified using the Qiagen RNeasy Mini Kit according to
the manufacturer’s protocol using 20–30 mg tissue. RNA integrity
was assessed using the RNA 6000 Nano LabChip by Bioanalyzer
(Agilent). Two micrograms of total RNA were reverse transcribed,
amplified, and labeled with Cy5 using a Low RNA Input
Amplification kit (Agilent). Common reference RNA consisted of
total RNA harvested from equal numbers of C57Bl6/J and 129
male and female Day 1 pups (courtesy of Dr. Cam Patterson, UNC).
Reference RNA was reverse transcribed, amplified, and labeled
with Cy3. The amplified sample and reference were co-hybridized
overnight to Agilent Mouse Oligo Microarrays (G4121A). They
were then washed and scanned on an Axon GenePix 4000B
scanner, analyzed using GenePix 4.1 software, and uploaded into
the UMD database (https://genome.unc.edu/) where Lowess
normalization is automatically performed. All data were submitted
to GEO (GSE34479). The genes for all analyses were filtered by: 1)
requiring intensity values in both channels to have a mean Lowess
normalized intensity of .10, 2) Values being reported in .70% of
the samples, and 3) the absolute value of the log2 of the ratio of
Channel 2/Channel 1 for at least three arrays having to be .1.6.
Hierarchical clustering was performed using Cluster v3.0 and
displayed using JavaTreeview v1.0.8.
We identified 871 differentially expressed TBP transcripts using
SAM implemented in BRB-ArrayTools (R. Simon and the BRB-
ArrayTools Development Team, NCI; Table 1; FDR 0.0485,
delta 0.92931). Gene ontology analyses were performed using the
FatiGO tool (Babelomics ver. 4.2, babelomics.bioinfo.cipf.es).
Mouse gene symbols were converted to human EntrezIDs using
Agilent annotations and the Mouse Genome Informatics database
of The Jackson Laboratory for comparisons. The Fisher’s exact
Figure 8. Comparative genomic hybridization. TBP tumors (n = 8) and TP tumors (n = 10) were analyzed by array CGH to identify copy number
aberrations (CNAs). Green lines to the right of the chromosome ideograms indicate gains and red lines to the left indicate losses of individual tumor
samples. No significant difference was found between the average number of CNAs between TBP and TP tumors (p = 0.8374). Frequent losses were
seen on chromosomes 4 and 10. Other recurrent losses included chromosome 7. Frequent gains were associated with chromosome 6.
doi:10.1371/journal.pgen.1003027.g008
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two-tailed test was used to determine significance of GO
(biological process [levels 3–9]) and KEGG pathway terms. Terms
with p,0.05 are reported.
Combined murine and human expression data sets
For the mouse tumor data set, IDs for 21,670 unfiltered probes
were retrieved (GSE34479). Human EntrezIDs were assigned to
orthologous genes as above. Mean values of redundant mouse
probes were calculated, missing values were imputed, the columns
were standardized to N(0,1), and the rows were median centered
using R (ver. 2.10.0). For the human data set, we downloaded the
file ‘‘UNC337arraydata_imputedCollapsed.txt’’ [4] from the
UNC MicroArray Database (genome.unc.edu). The two data sets
were corrected for systemic biases using Distance Weighted
Discrimination [46]. The combined data set was used for centroid
linkage hierarchical clustering analysis.
CGH analysis
We performed array CGH essentially as previously described
[47]. Briefly, genomic DNA was isolated from tumors, fluores-
cently labeled, and competitively hybridized with wt DNA spotted
BAC (Bacterial Artificial Chromosomes) arrays. All data were
submitted to GEO (GSE40925). We used the HaarSeg algorithm
with default parameters implemented in waviCGH (wavi.bioin-
fo.cnio.es) for chromosomal segmentation of mutations and for
CNA calling. We manually curated BAC clones spanning putative
CNAs with a conservative tumor:normal DNA threshold of
log2ratio .0.5 or ,20.5. Genes mapping to the BAC clones
were identified using the National Center for Biotechnology Map
Viewer and the Jackson Laboratory Mouse Genome Database.
Gene lists were compared to the Cancer Gene Census (Sanger
Institute), the KEGG Pathways in Cancer, Atlas Genetics
Oncology, and the Michigan Molecular Interactions database.
For the pathway analysis, we used the SAM algorithm
implemented in BRB-Array Tools to identify differentially
expressed genes (TBP_SAM) among TBP tumors versus the rest
of the mouse tumors in the data set. We interrogated KEGG
(TBP_KEGG) and GO (TBP_GO_BP) databases using the
FatiGO algorithm implemented in the Babelomics (ver. 4.2) suite
of bioinformatics tools (babelomics.bioinfo.cipf.es). We compared
these results to the differentially expressed genes reported by Prat
et al. (2010) of human Claudin-low (CL_KEGG, CL_GO_BP)
and Basal-like (Basa_KEGG, Basal-_GO_BP) tumors. We also
used the FatiGO tool in the Babelomics 4.3.0 integrative platform
with parameters set for the Fisher’s exact two-tailed test to
determine the most alternately expressed KEGG pathways among
the amplified genes determined by CGH analysis.
Supporting Information
Figure S1 Hierarchical clustering of the cross-species analysis
summarized in Figure 5.
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File S1 Tumor annotations (Table S1 Tumor_Descriptors).
Differentially expressed genes defined by SAM analysis of TBP
tumors (S2 TBP_SAM). Gene Ontology (GO) terms enriched
among tumor TBP, Basal, and Claudin-low subtypes (S3
TBP_GO_BP, S4 Basal_GO_BP, and S5 CL_GO_BP). KEGG
pathways enriched among the tumor subtypes (S6 TBP_KEGG,
S7 Basal_KEGG, S8 CL_KEGG). Among all tumors assayed
(n= 18), we identified nearly five-hundred loci with potential copy-
number gains (log2ratio .0.5, Table S9 putative_gained_CGH_-
loci). Approximately half of the genes are previously defined
oncogenes represented in oncogene lists including the Cancer
Gene Census (Sanger Institute) and the KEGG Pathways in
Cancer. The KEGG Pathways enriched among putative gained
genes (Table S10 CGH_Gain_KEGG).
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